BioLineRx Statistics
Total Valuation
BioLineRx has a market cap or net worth of $11.87 million. The enterprise value is $7.26 million.
Important Dates
The next estimated earnings date is Tuesday, May 27, 2025, before market open.
| Earnings Date | May 27, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
BioLineRx has 2.23 billion shares outstanding. The number of shares has increased by 24.37% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 2.23B |
| Shares Change (YoY) | +24.37% |
| Shares Change (QoQ) | +9.05% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 2.13B |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.41 |
| Forward PS | n/a |
| PB Ratio | 0.88 |
| P/TBV Ratio | 3.94 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.25 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.76, with a Debt / Equity ratio of 1.12.
| Current Ratio | 1.76 |
| Quick Ratio | 1.52 |
| Debt / Equity | 1.12 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -2.11 |
Financial Efficiency
Return on equity (ROE) is -69.11% and return on invested capital (ROIC) is -44.90%.
| Return on Equity (ROE) | -69.11% |
| Return on Assets (ROA) | -23.28% |
| Return on Invested Capital (ROIC) | -44.90% |
| Return on Capital Employed (ROCE) | -81.50% |
| Revenue Per Employee | $1.03M |
| Profits Per Employee | -$329,321 |
| Employee Count | 28 |
| Asset Turnover | 0.56 |
| Inventory Turnover | 3.63 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -88.15% in the last 52 weeks. The beta is 0.86, so BioLineRx's price volatility has been lower than the market average.
| Beta (5Y) | 0.86 |
| 52-Week Price Change | -88.15% |
| 50-Day Moving Average | 3.08 |
| 200-Day Moving Average | 12.79 |
| Relative Strength Index (RSI) | 47.96 |
| Average Volume (20 Days) | 18,371 |
Short Selling Information
| Short Interest | 198,765 |
| Short Previous Month | 217,240 |
| Short % of Shares Out | 5.85% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 7.45 |
Income Statement
In the last 12 months, BioLineRx had revenue of $28.94 million and -$9.22 million in losses. Loss per share was -$0.01.
| Revenue | 28.94M |
| Gross Profit | 19.68M |
| Operating Income | -19.15M |
| Pretax Income | -49.15M |
| Net Income | -9.22M |
| EBITDA | -15.70M |
| EBIT | -19.15M |
| Loss Per Share | -$0.01 |
Full Income StatementBalance Sheet
The company has $19.56 million in cash and $15.04 million in debt, giving a net cash position of $4.52 million or $0.00 per share.
| Cash & Cash Equivalents | 19.56M |
| Total Debt | 15.04M |
| Net Cash | 4.52M |
| Net Cash Per Share | $0.00 |
| Equity (Book Value) | 13.46M |
| Book Value Per Share | 0.01 |
| Working Capital | 11.70M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$43.87 million and capital expenditures -$53,000, giving a free cash flow of -$43.93 million.
| Operating Cash Flow | -43.87M |
| Capital Expenditures | -53,000 |
| Free Cash Flow | -43.93M |
| FCF Per Share | -$0.02 |
Full Cash Flow StatementMargins
Gross margin is 67.99%, with operating and profit margins of -66.18% and -31.86%.
| Gross Margin | 67.99% |
| Operating Margin | -66.18% |
| Pretax Margin | -31.86% |
| Profit Margin | -31.86% |
| EBITDA Margin | -54.25% |
| EBIT Margin | -66.18% |
| FCF Margin | n/a |
Dividends & Yields
BioLineRx does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -24.37% |
| Shareholder Yield | -24.37% |
| Earnings Yield | -77.68% |
| FCF Yield | -370.03% |
Analyst Forecast
The average price target for BioLineRx is $26.00, which is 741.42% higher than the current price. The consensus rating is "Buy".
| Price Target | $26.00 |
| Price Target Difference | 741.42% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
The last stock split was on January 30, 2025. It was a reverse split with a ratio of 0.025:1.
| Last Split Date | Jan 30, 2025 |
| Split Type | Reverse |
| Split Ratio | 0.025:1 |
Scores
BioLineRx has an Altman Z-Score of -13.48 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -13.48 |
| Piotroski F-Score | 3 |